Tags

Type your tag names separated by a space and hit enter

Ibrutinib in the management of Waldenstrom macroglobulinemia.
J Oncol Pharm Pract. 2019 Mar; 25(2):434-441.JO

Abstract

Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients who have failed treatment with other agents, has emerged as an important therapeutic agent in the management of Waldenstrom macroglobulinemia and other plasma cell dyscrasias. Ibrutinib has shown to increase progression free survival and improve overall mortality. We present a review of ibrutinib, beginning with an overview of the Bruton tyrosine kinase pathway and clinically relevant gene mutations impacting treatment and prognosis for patients with Waldenstrom macroglobulinemia, followed by evidence supporting therapeutic indications for ibrutinib, and detailing its safety and efficacy evidence, current clinical guidelines, adverse effects and their management, and finally challenges of drug resistance. We also present findings on newly developed Bruton tyrosine kinase inhibitors in the therapeutic pipeline to provide readers insight into this rapidly evolving corner of oncology pharmacy practice.

Authors+Show Affiliations

1 Grand Strand Regional Medical Center, Myrtle Beach, USA.2 Coastal Cancer Center, Myrtle Beach, USA.1 Grand Strand Regional Medical Center, Myrtle Beach, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29996737

Citation

Yosef, Amir, et al. "Ibrutinib in the Management of Waldenstrom Macroglobulinemia." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 25, no. 2, 2019, pp. 434-441.
Yosef A, Touloukian EZ, Nambudiri VE. Ibrutinib in the management of Waldenstrom macroglobulinemia. J Oncol Pharm Pract. 2019;25(2):434-441.
Yosef, A., Touloukian, E. Z., & Nambudiri, V. E. (2019). Ibrutinib in the management of Waldenstrom macroglobulinemia. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 25(2), 434-441. https://doi.org/10.1177/1078155218786037
Yosef A, Touloukian EZ, Nambudiri VE. Ibrutinib in the Management of Waldenstrom Macroglobulinemia. J Oncol Pharm Pract. 2019;25(2):434-441. PubMed PMID: 29996737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ibrutinib in the management of Waldenstrom macroglobulinemia. AU - Yosef,Amir, AU - Touloukian,Emily Z, AU - Nambudiri,Vinod E, Y1 - 2018/07/12/ PY - 2018/7/13/pubmed PY - 2019/3/21/medline PY - 2018/7/13/entrez KW - Bruton tyrosine kinase inhibitors KW - CXCR4 KW - Ibrutinib KW - MYD88 KW - Waldenstrom macroglobulinemia SP - 434 EP - 441 JF - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners JO - J Oncol Pharm Pract VL - 25 IS - 2 N2 - Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients who have failed treatment with other agents, has emerged as an important therapeutic agent in the management of Waldenstrom macroglobulinemia and other plasma cell dyscrasias. Ibrutinib has shown to increase progression free survival and improve overall mortality. We present a review of ibrutinib, beginning with an overview of the Bruton tyrosine kinase pathway and clinically relevant gene mutations impacting treatment and prognosis for patients with Waldenstrom macroglobulinemia, followed by evidence supporting therapeutic indications for ibrutinib, and detailing its safety and efficacy evidence, current clinical guidelines, adverse effects and their management, and finally challenges of drug resistance. We also present findings on newly developed Bruton tyrosine kinase inhibitors in the therapeutic pipeline to provide readers insight into this rapidly evolving corner of oncology pharmacy practice. SN - 1477-092X UR - https://www.unboundmedicine.com/medline/citation/29996737/Ibrutinib_in_the_management_of_Waldenstrom_macroglobulinemia_ L2 - http://journals.sagepub.com/doi/full/10.1177/1078155218786037?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -